Kristensen Lasse S, Jakobsen Theresa, Hager Henrik, Kjems Jørgen
Department of Biomedicine, Aarhus University, Aarhus C, Denmark.
Department of Clinical Pathology, Vejle Hospital, Vejle, Denmark.
Nat Rev Clin Oncol. 2022 Mar;19(3):188-206. doi: 10.1038/s41571-021-00585-y. Epub 2021 Dec 15.
Over the past decade, circular RNAs (circRNAs) have emerged as a large class of primarily non-coding RNA molecules, many of which have key roles in cancer development and progression through diverse mechanisms of action. CircRNAs often have tissue-restricted and cancer-specific expression patterns, and accumulating data suggest that these molecules are of potential clinical relevance and utility. In particular, circRNAs have strong potential as diagnostic, prognostic and predictive biomarkers, which is underscored by their detectability in liquid biopsy samples such as in plasma, saliva and urine. However, technical issues in the detection and assessment of circRNAs as well as biological knowledge gaps need to be addressed to move this relatively young field of research forward and bring circRNAs to the forefront of clinical practice. Herein, we review the current knowledge regarding circRNA biogenesis, regulation and functions in cancer as well as their clinical potential as biomarkers, therapeutic agents and drug targets.
在过去十年中,环状RNA(circRNAs)已成为一大类主要的非编码RNA分子,其中许多通过多种作用机制在癌症发生和发展中发挥关键作用。CircRNAs通常具有组织限制性和癌症特异性表达模式,越来越多的数据表明这些分子具有潜在的临床相关性和实用性。特别是,circRNAs作为诊断、预后和预测生物标志物具有很大潜力,其在血浆、唾液和尿液等液体活检样本中的可检测性突出了这一点。然而,要推动这个相对年轻的研究领域向前发展并使circRNAs成为临床实践的前沿,需要解决circRNAs检测和评估中的技术问题以及生物学知识空白。在此,我们综述了关于circRNA在癌症中的生物发生、调控和功能以及它们作为生物标志物、治疗剂和药物靶点的临床潜力的当前知识。